IL17 has been shown to regulate the fibrotic response in proinflammatory conditions such as psoriasis and pulmonary/liver fibrosis (Lei et al., 2016; Zhang et al., 2019; Seki and Brenner, 2015; Blauvelt and Chiricozzi, 2018), while relaxin has a well-established role in suppressing myofibroblast activation and ECM remodeling (Ng et al., 2019; Martin et al., 2019; Samuel et al., 2017). This evidence concerns the gene IL17A and Hepatic fibrosis.